Status:
COMPLETED
Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fasting Conditions
Lead Sponsor:
Roxane Laboratories
Conditions:
Seizures
Eligibility:
FEMALE
18-45 years
Phase:
NA
Brief Summary
The objective of this study was to prove the bioequivalence of Levetiracetam 750 mg Tablets under fasted conditions
Eligibility Criteria
Inclusion
- No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening
Exclusion
- Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to Levetiracetam or any comparable or similar product.
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2005
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00826865
Start Date
August 1 2005
End Date
August 1 2005
Last Update
January 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MDS Pharma Services
Phoenix, Arizona, United States, 85044